Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products Insulin Reagent and Calibrators have received FDA clearance and the CE mark. The assay is expected to be commercially available for use on all of the company’s Vitros immunodiagnostic and integrated systems in Europe, in other countries accepting the CE mark, and in the U.S. during the third quarter of this year.
October 2017—The Clinical and Laboratory Standards Institute has published a microbiology guideline, “M58: Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry, 1st ed.”
October 2017—Baebies, a Durham, NC–based company focused on advancing newborn screening and pediatric testing, has signed a bilateral distribution agreement with Trivitron’s Labsystems Diagnostics to deliver newborn screening solutions to several markets worldwide. Baebies will distribute Labsystems’ newborn screening products NeoMass AAAC and NS 2400 in the United States after obtaining regulatory clearance.
October 2017—Metabolon has acquired Metabolomic Discoveries, a metabolomics services and diagnostics company based near Berlin, Germany.
October 2017—Thermo Scientific Samco Clicktainer leakproof vials have been developed to provide sample protection and user safety by enabling correct cap application. The vials are designed for the secure collection and handling of fluid, solid, and powder samples, including urine, sputum, and stool specimens; the lid-lock design makes them ideal for the secure transport of clinical, research, and forensic samples.
October 2017—PerkinElmer is collaborating with In-Depth Genomics to support IDG’s whole genome sequencing diagnostic program, which will bring genetic diagnosis to patients who have a wide range of neurological conditions, including orphan disorders, and aims to provide improved diagnoses and treatments.
October 2017—Ambry Genetics and NorthShore University HealthSystem’s Center for Personalized Medicine (Evanston, Ill.) will partner to offer genetic testing and research to advance precision medicine in preventive care.
October 2017—Bio-Rad Laboratories announced FDA clearance for its BioPlex 2200 ToRC IgM Assay, a fully automated assay for the detection of IgM class antibodies to Toxoplasma gondii, rubella, and cytomegalovirus offered in a multiplexed panel.
October 2017—Morphotek, a subsidiary of Eisai, has entered into a collaboration and license agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay for use on the Lumipulse system as a companion diagnostic to aid in the selection of ovarian cancer patients who may best respond to farletuzumab.
October 2017—TechLab received FDA clearance for the Tri-Combo Parasite Screen test. The test is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. It specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic E. dispar.
